This trial will test a new cancer treatment involving two immunotherapy drugs given before surgery, and one drug given for a year after surgery.
2 Primary · 3 Secondary · Reporting Duration: 5 years
Experimental Treatment
30 Total Participants · 2 Treatment Groups
Primary Treatment: Nivolumab Injection · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: